Abstract
BackgroundCyclin D1 (CCND1) plays a key role in cell cycle regulation. It is a well-established human oncogene which is frequently amplified or overexpressed in cancers. The association between CCND1 G870A polymorphism and cancer risk has been widely assessed. However, a definitive conclusion between CCND1 G870A polymorphism and risk of nasopharyngeal carcinoma (NPC) remains elusive.MethodsWe firstly performed a hospital-based case-control study involving 165 NPC cases and 191 cancer-free controls in central-south China, and then conducted a meta-analysis with six case-control studies to evaluate the association between NPC risk and CCND1 G870A polymorphism.ResultsThe case-control study found a significant association between CCND1 G870A polymorphism and NPC risk in various comparison models (AA vs. GG: OR = 2.300, 95% CI 1.089–4.857, p = 0.029; AG vs. GG: OR = 2.832, 95% CI 1.367–5.867, p = 0.005; AA/AG vs. GG: OR = 2.597, 95% CI 1.288–5.237, p = 0.008; AA vs. AG/GG: OR = 0.984, 95% CI 0.638–1.518, p = 0.944). Further meta-analysis showed that there was no significant association between CCND1 G870A polymorphism and NPC risk in overall analysis. In the stratified analysis by race, however, significant associations were only found in Caucasians (for the allele model A vs. G: OR = 0.75, 95% CI 0.59–0.97, p = 0.03; for the co-dominant model AA vs. GG: OR = 0.52, 95% CI 0.32–0.86, p = 0.01; for the dominant model AA/AG vs. GG: OR = 0.49, 95% CI 0.32–0.74, p<0.01; for the recessive model AA vs. AG/GG: OR = 0.90, 95% CI 0.61–1.34, p = 0.60).ConclusionsA significant association between CCND1 G870A polymorphism and NPC risk was found in the central-southern Chinese population. The meta-analysis indicated that CCND1 G870A polymorphism may contribute to the development of NPC in Caucasians.
Highlights
Nasopharyngeal carcinoma (NPC) is considered as one of the rarer cancer forms globally and has a significantly different ethnic and geographic distribution [1]
The Cyclin D1 (CCND1) G870A polymorphism showed significant difference between nasopharyngeal carcinoma (NPC) patients and healthy controls in genotype comparison (AA vs. GG: odds ratio (OR) = 2.291, 95% confidence interval (CI) 1.086–4.833, p = 0.030; AG vs. GG: OR = 2.788, 95% confidence intervals (95% CIs) 0.350–5.756, p = 0.006; AA/AG vs. GG: OR = 2.566, 95% CI 1.275–5.165, p = 0.008; AA vs. AG/GG: OR = 0.991, 95% CI 0.644–1.526, p = 0.968,Table 2)
Similar significant differences were found in age-adjusted logistic regression analysis (AA vs. GG: OR = 2.300, 95% CI 1.089–4.857, p = 0.029; AG vs. GG: OR = 2.832, 95% CI 1.367–5.867, p = 0.005; AA/AG vs. GG: OR = 2.597, 95% CI 1.288–5.237, p = 0.008; AA vs. AG/GG: OR = 0.984, 95% CI 0.638–1.518, p = 0.944, Table 2)
Summary
Nasopharyngeal carcinoma (NPC) is considered as one of the rarer cancer forms globally and has a significantly different ethnic and geographic distribution [1]. The abnormality of G1-S phase progression of the cell cycle is one of the hallmarks of cancer. It is frequently amplified or overexpressed in cancers, such as breast cancer, lung cancer, colorectal cancer, melanoma and oral squamous cell carcinomas, through copy number. Cyclin D1 (CCND1) plays a key role in cell cycle regulation. It is a well-established human oncogene which is frequently amplified or overexpressed in cancers. A definitive conclusion between CCND1 G870A polymorphism and risk of nasopharyngeal carcinoma (NPC) remains elusive
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
